A Study to Assess Safety, Tolerability and PK of AZD2171 and Chemotherapy on Patients With Solid Tumors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

104 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-01-31

Study Completion Date

2011-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A multicentre, 2-part study to assess the safety and tolerability of once daily oral doses of AZD2171 when administered with various anticancer regimens (part A) and to confirm the tolerability of its combination with FOLFOX (part B).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Absorption, Metabolism, Excretion and Pharmacokinetics of a Single Dose [14C]AZD2014 Followed by a Multiple Dose Phase

NCT02640755

Solid Malignancies

COMPLETED PHASE1

Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD6918

NCT00733031

Cancer, Solid Tumors Advanced Solid Malignancies

TERMINATED PHASE1

Phase I Study of AZD2171 co-Administered With Fixed Multiple Oral Doses of ZD1839 in Patients With Advanced Cancer

NCT00502060

Advanced Tumor

COMPLETED PHASE1

Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours

NCT00475956

Neoplasms

COMPLETED PHASE1

Study to Assess Safety of AZD7762 Administered Alone and in Combination With Gemcitabine in Patients With Advanced Solid Malignancies

NCT00413686

Solid Tumors

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced Solid Tumor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AZD2171

oral tablet once daily

Intervention Type DRUG

FOLFOX

intravenous infusion

Intervention Type DRUG

Pemetrexed

intravenous infusion

Intervention Type DRUG

Irinotecan (administered with & without Cetuximab)

intravenous injection

Intervention Type DRUG

Docetaxel

intravenous infusion

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

cediranib RECENTIN™. 5-Fluorouracil, Leucovorin and Oxaliplatin Alimta® Pemetrexed disodium Campto® Camptosar® irinotecan hydrochloride Taxotere®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* histologically confirmed metastatic cancer that is not amenable to surgery or radiation therapy with curative intent
* measurable lesion by CT or other techniques according to RECIST